| Name | Z-Leu-Leu-Norvalinal |
|---|---|
| Synonyms |
L-Leucinamide, N-[(phenylmethoxy)carbonyl]-L-leucyl-N-[(1S)-1-formylbutyl]-
N-[(Benzyloxy)carbonyl]-L-leucyl-N-[(2S)-1-oxo-2-pentanyl]-L-leucinamide benzyl N-[(2S)-4-methyl-1-[[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxopentan-2-yl]amino]pentan-2-yl]amino]-1-oxopentan-2-yl]carbamate MG115 Z-LLnV |
| Description | MG-115 is a potent and reversible proteasome inhibitor, with Kis of 21 nM and 35 nM for 20S and 26S proteasome, respectively. MG-115 specifically inhibit the chymotrypsin-like activity of the proteasome, induces p53-dependent apoptosis[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
Ki: 21 nM (20S proteasome); 35 nM (26 Sproteasome)[1] |
| In Vitro | MG-115 (0.1-10 μM; 24 h) dose-dependently decreases the viability of HepG2 cells[3]. MG-115 (0.1-10 μM; 24 h) amplifies the reporter gene expression mediated by CWK18 DNA condensates[3]. Cell Viability Assay[3] Cell Line: HepG2 cells Concentration: 0.1, 1, 2, 5, 10 μM Incubation Time: 24 hours Result: Dose-dependently decreased cell viability. Inhibited the proteasomal activity, with an IC50 of 2 μM. |
| References |
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 678.8±55.0 °C at 760 mmHg |
| Molecular Formula | C25H39N3O5 |
| Molecular Weight | 461.59 |
| Flash Point | 364.3±31.5 °C |
| Exact Mass | 461.288971 |
| PSA | 113.60000 |
| LogP | 5.41 |
| Vapour Pressure | 0.0±2.1 mmHg at 25°C |
| Index of Refraction | 1.508 |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | NONH for all modes of transport |